Capricor Therapeutics (CAPR) came out with a quarterly loss of $0.31 per share versus the Zacks Consensus Estimate of a loss of $0.11. This compares to loss of $0.31 per share a year ago. These figures are adjusted for non-recurring items.This quarterly report represents an earnings surprise of -181.82%. A quarter ago, it was expected that this biotechnology company would post a loss of $0.23 per share when it actually produced a loss of $0.02, delivering a surprise of 91.30%.Over the last four quarters, th ...